Increased plasma thrombin-antithrombin III complex levels in non-insulin dependent diabetic patients with albuminuria are reduced by ethyl icosapentatenoate. 1995

H Shimizu, and K Ohtani, and Y Tanaka, and A Fukatsu, and Y Uehara, and N Sato, and M Mori
First Department of Internal Medicine, Gunma University School of Medicine, Japan.

Hypercoagulability may increase the risk of cardiovascular disease (CVD) in diabetic patients with albuminuria. Plasma thrombin-anti-thrombin III complex (TAT) levels, representing a functional state of clotting system, were studied in one hundred and fifteen non-insulin-dependent diabetic (NIDDM) patients. The patients were divided into three groups according to the urine albumin index (UAI: mg/g Cr): Group A; UAI < 30, Group B; 30 < UAI < 300, Group C; UAI > 300. The effect of albuminuria on plasma TAT levels was significant (p < 0.02). Ethyl icosapentatenoate (EPA: 1800 mg/day) for 4 weeks significantly (p < 0.0005) decreased plasma TAT levels. These data indicate that the degree of diabetic albuminuria is related to plasma TAT levels in NIDDM patients and that treatment with EPA may reduce TAT levels and possibly therefore the rate of development of CVD in patients with NIDDM.

UI MeSH Term Description Entries
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000419 Albuminuria The presence of albumin in the urine, an indicator of KIDNEY DISEASES. Albuminurias
D000990 Antithrombin III A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily. Heparin Cofactor I,Antithrombin III-Alpha,Atenativ,Heparin Co-Factor I,Kybernin,Serpin C1,Thrombate III,Antithrombin III Alpha,Antithrombin IIIAlpha,Cofactor I, Heparin,Heparin Co Factor I
D015118 Eicosapentaenoic Acid Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families. 5,8,11,14,17-Eicosapentaenoic Acid,Icosapent,5,8,11,14,17-Icosapentaenoic Acid,Eicosapentanoic Acid,Timnodonic Acid,omega-3-Eicosapentaenoic Acid,Acid, Eicosapentanoic,omega 3 Eicosapentaenoic Acid

Related Publications

H Shimizu, and K Ohtani, and Y Tanaka, and A Fukatsu, and Y Uehara, and N Sato, and M Mori
November 1988, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
H Shimizu, and K Ohtani, and Y Tanaka, and A Fukatsu, and Y Uehara, and N Sato, and M Mori
December 1988, Rinsho byori. The Japanese journal of clinical pathology,
H Shimizu, and K Ohtani, and Y Tanaka, and A Fukatsu, and Y Uehara, and N Sato, and M Mori
October 2012, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
H Shimizu, and K Ohtani, and Y Tanaka, and A Fukatsu, and Y Uehara, and N Sato, and M Mori
May 1996, Gynecologic oncology,
H Shimizu, and K Ohtani, and Y Tanaka, and A Fukatsu, and Y Uehara, and N Sato, and M Mori
January 1999, Kidney international,
H Shimizu, and K Ohtani, and Y Tanaka, and A Fukatsu, and Y Uehara, and N Sato, and M Mori
April 2001, Pediatrics international : official journal of the Japan Pediatric Society,
H Shimizu, and K Ohtani, and Y Tanaka, and A Fukatsu, and Y Uehara, and N Sato, and M Mori
November 1991, Scandinavian journal of gastroenterology,
H Shimizu, and K Ohtani, and Y Tanaka, and A Fukatsu, and Y Uehara, and N Sato, and M Mori
March 1993, The Journal of thoracic and cardiovascular surgery,
H Shimizu, and K Ohtani, and Y Tanaka, and A Fukatsu, and Y Uehara, and N Sato, and M Mori
August 1989, Biochimica et biophysica acta,
Copied contents to your clipboard!